ea0063p619 | Diabetes, Obesity and Metabolism 2 | ECE2019
Allas Soraya
, Mohideen Pharis
, Delale Thomas
, Lin Vivian
, Yeh Michael
, Tremel Nadege
, Tauber Maithe
Background: Prader-Willi syndrome (PWS) is a rare disease characterized by hyperphagia and abnormal food-related behaviors that contribute to severe morbidity and early mortality and to a significant burden on patients and caregivers. There is no approved treatment for hyperphagia in PWS. Patients with PWS have increased circulating levels of the orexigenic hormone acylated ghrelin (AG) with a relative deficit of unacylated ghrelin (UAG). Livoletide (AZP-531) is a first-in-cla...